How Long to Take Allergy Shots: The 3-Year vs 5-Year Evidence Debate

The most influential study on stopping allergy shots at 3 years is Durham et al.'s landmark trial published in NEJM 1999, which followed adults who received 3 to 4 years of grass pollen SCIT. After discontinuation, symptom and medication scores remained as low as during continued maintenance for at least 3 more years — demonstrating true disease modification that persists after stopping. This study established the scientific basis for the 3-year minimum recommendation. The AAAAI practice parameters by Cox et al. in JACI 2011 cite this and related studies when recommending that patients complete at least 3 years of maintenance before considering stopping.

The primary evidence for extended SCIT duration comes from Eng et al.'s long-term follow-up published in Allergy 2006, which documented sustained clinical benefit 12 years after a childhood preseasonal grass SCIT course — substantially longer than the 3-year post-treatment benefit documented by Durham et al. Shamji and Durham in JACI 2017 provided mechanistic support: longer treatment is associated with more sustained IgG4 blocking antibody production and deeper regulatory T-cell (Treg) memory, which may explain more durable post-treatment tolerance. European allergists have historically tended toward 3 years as standard, while US allergists more often extend to 4 to 5 years for polysensitized patients or those with asthma.

No randomized controlled trial has directly compared 3-year versus 5-year SCIT courses using the same protocol for the same allergen — this is a recognized gap in the evidence base. The comparison between Durham 1999 (3-to-4-year course) and Eng 2006 (longer course with greater durability) is indirect and involves different patient populations, different protocols, and different time periods. The AAAAI practice parameters acknowledge this evidence gap explicitly. The 3-vs-5-year recommendation therefore rests on clinical judgment, indirect evidence from separate trials, and mechanistic data suggesting longer treatment produces deeper immune tolerance. This limitation should be part of any informed consent discussion with patients considering extended treatment.

Patients most likely to benefit from extending allergy shots to 5 years include those who are polysensitized (sensitized to multiple unrelated allergens requiring complex extract formulation), have asthma comorbidity alongside allergic rhinitis, show persistent symptoms at the 3-year mark without complete remission, and younger patients who face decades of ongoing allergen exposure. Additionally, patients who experienced slower-than-average symptom improvement during the first 1 to 2 years of maintenance may benefit from continued treatment to allow deeper immune tolerance to develop. The AAAAI practice parameters specifically note that the decision to extend beyond 3 years should be individualized based on clinical response and patient preference.

There is a historical transatlantic difference in SCIT duration practice. European allergists and EAACI guidelines (Roberts et al., Allergy 2018) have generally cited 3 years as the minimum and standard duration, often using single-allergen protocols even for polysensitized patients. US allergists, whose practice parameters (Cox et al., JACI 2011) also specify 3 years as minimum, more commonly extend treatment to 4 to 5 years — particularly given the US practice of multi-allergen extract formulations for polysensitized patients. The EAACI guidelines and US AAAAI/ACAAI parameters are broadly aligned on the 3-year minimum; the difference lies in typical real-world practice patterns and the multi-allergen vs single-allergen approach.

Factors that support discontinuing allergy shots at 3 years include monosensitization to a single well-characterized allergen (e.g., grass pollen only), rapid and complete symptom resolution during maintenance, successful elimination of daily rescue medications, absence of asthma comorbidity, sustained symptom control through 2 or more full allergen seasons, patient preference for the shortest effective course (67 percent of patients prefer the shortest effective course per survey data), and cost or logistical constraints that make extended treatment genuinely unsustainable. If all these conditions are met and the patient has achieved the goals of treatment, 3 years is a clinically reasonable stopping point supported by the Durham et al. evidence.

If allergy shots show no clinical benefit after a full year at the maintenance dose, discontinuation may be appropriate — regardless of how long you have been on treatment. The AAAAI and ACAAI practice parameters recommend evaluating SCIT response after at least 1 year at the maintenance dose. If there is no measurable benefit after this evaluation, the allergist should reassess allergen selection, dosing adequacy, and whether confounding factors (uncontrolled asthma, undiscovered additional allergens, poor extract quality) are limiting response. Continuing an ineffective treatment for an additional 1 to 3 years would not be appropriate. However, a 2-year course with confirmed clinical improvement does not represent a completed course — benefits from stopping at 2 years are less durable than from completing 3-plus years.